3 Subtle Investing Mistakes I Won't Repeat in 2025 And Beyond


ywAAAAAAQABAAACAUwAOw==

It’s normal to make more than a few flubs while investing, especially when you’re new. At the same time, we owe it to ourselves to be humble and to recognize when we’ve made a mistake with our finances. There’s no point in beating yourself up, but there’s a big point to understanding what went wrong and how to do it better the next time — after all, there’s money on the line.

Not every mistake has to be a catastrophe, obviously. But it’s still worth ironing out the kinks in your investing habits, especially if you plan to be investing for decades to come. With that in mind, I’d like to share three examples of less-serious oversights I made in 2024 so that you can (hopefully) avoid them in your own investing life.

One of my rules is that I need to have a strong and pithy investment thesis for every investment I make, and for any that I write about, too. But an investment thesis simply can’t be a monolith that stands unchanged over time, as markets are constantly changing, and businesses are constantly updating their strategies to compete more effectively both today and in the future.

The more complicated the industry and the more complicated the company, the more moving parts there are for the investor to take into account when formulating a thesis, which entails a larger responsibility to update the thesis more frequently. Even when broadly upholding that responsibility, it’s still very possible to miss the forest for the trees, as I did with Pfizer (NYSE: PFE).

Since roughly 2020, my investment thesis called for Pfizer to be a favorable stock to buy and hold because of its large portfolio of pharmaceuticals and its demonstrated competency in research and development (R&D), as reflected by its massive pipeline.

Nonetheless, the stock is down by 45% over the last three years, badly underperforming the market’s gain of 31%. Clearly, something wasn’t working, but I kept circling back to the same factors that were originally in my investment thesis, finding them to still be sound.

Then, late in 2024, an activist investing group called Starboard Value said that it had taken a $1 billion stake in Pfizer with the goal of improving the company’s efficiency. The group published a report outlining many areas where it thought that the company was struggling, including specifically its R&D efficiency and its capital allocation strategy.

Reading the report, I was gobsmacked; the activist group had essentially explained to me quite fastidiously that my investment thesis was no longer accurate. I immediately changed my stance on the stock to be a bit more bearish.



Source link

About The Author

Scroll to Top